BiotechTube

UPLIZNA

Pre-clinicalRecruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuromyelitis Optica Spectrum Disorder

Conditions

Neuromyelitis Optica Spectrum Disorder, Pregnancy Related

Trial Timeline

Apr 15, 2026 → Oct 31, 2032

NCT ID
NCT05909761

About UPLIZNA

UPLIZNA is a pre-clinical stage product being developed by Amgen for Neuromyelitis Optica Spectrum Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05909761. Target conditions include Neuromyelitis Optica Spectrum Disorder, Pregnancy Related.

What happened to similar drugs?

2 of 6 similar drugs in Neuromyelitis Optica Spectrum Disorder were approved

Approved (2) Terminated (1) Active (4)
✅Satralizumab 120 mgChugai PharmaceuticalApproved
✅InebilizumabAmgenApproved
🔄Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3
🔄satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
🔄SatralizumabRochePhase 3

Hype Score Breakdown

Clinical
3
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06590051Pre-clinicalActive
NCT05909761Pre-clinicalRecruiting

Competing Products

8 competing products in Neuromyelitis Optica Spectrum Disorder

See all competitors
ProductCompanyStageHype Score
Satralizumab 120 mgChugai PharmaceuticalApproved
35
Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
40
Satralizumab + PlaceboChugai PharmaceuticalPhase 3
40
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
40
SatralizumabRochePhase 3
47
InebilizumabAmgenPhase 2
42
InebilizumabAmgenApproved
47
intravenous methylprednisoloneBrain BiotechPre-clinical
23